O Sistema Endocanabinóide – uma perspetiva terapêutica
Resumo
A utilização terapêutica da Cannabis sativa ou seus derivados é conhecida há muitos anos, no entanto, o estudo das suas propriedades despontou recentemente com a descoberta de um sistema canabinóide endógeno (ECS). O ECS compreende os compostos endógenos similares ao tetrahidrocanabinol (endocanabinóides), os recetores canabinóides (CB1 e CB2) e as enzimas envolvidas no seu metabolismo. Desde a descoberta do ECS, a comunidade científica focou-se na investigação do seu potencial clínico com resultados encorajadores. Em alguns países, os derivados da cannabis constituem uma opção farmacológica na estimulação do apetite e tratamento da dor. O primeiro medicamento baseado no ECS, o rimonabant (um antagonista CB1), foi aprovado para o tratamento da obesidade associada a outros fatores de risco, no entanto foi retirado por questões de segurança. Atualmente, e baseadas nos estudos pré-clínicos e clínicos, existem várias evidências do seu interesse clínico na modulação de diversas condições fisiopatológicas. Neste artigo discutimos o papel potencial do sistema (endo)canabinóide na terapêutica e as recentes estratégias desenvolvidas na modulação do sistema.
Referências
Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Testing and Analysis. 2013 Sep 4, (Doi: 10.1002/dta.1529).
Mechoulam R, Gaoni Y. A Total Synthesis of Dl- Delta-1-Tetrahydrocannabinol, the Active Constit- uent of Hashish. J Am Chem Soc. 1965; 87:3273-5.
Pertwee RG. Targeting the endocannabinoid sys- tem with cannabinoid receptor agonists: phar- macological strategies and therapeutic possibili- ties. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3353-63.
Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characteriza- tion of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605-13.
Devane WA, Hanus L, Breuer A, Pertwee RG, Ste- venson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabi- noid receptor. Science. 1992; 258(5090):1946-9.
Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for can- nabinoids. Nature. 1993; 365(6441):61-5.
Fonseca BM, Costa MA, Almada M, Correia-da- Silva G, Teixeira NA. Endogenous cannabinoids revisited: a biochemistry perspective. Prostaglan- dins Other Lipid Mediat. 2013; 102-103:13-30.
FowlerCJ.Transportofendocannabinoidsacross the plasma membrane and within the cell. FEBS J. 2013; 280(9):1895-904.
Pacher P, Kunos G. Modulating the endocannabi- noid system in human health and disease--suc- cesses and failures. FEBS J. 2013; 280(9):1918-43.
Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of can- nabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3364-78.
Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid ac- tivation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005; 115(5):1298-305.
Maresz K, Pryce G, Ponomarev ED, Marsicano G,Croxford JL, Shriver LP, et al. Direct suppression of CNS autoimmune inflammation via the canna- binoid receptor CB(1) on neurons and CB(2) on autoreactive T cells. Nat Med. 2007; 13(4):492-7.
Fonseca BM, Correia-da-Silva G, Taylor AH, Lam PM, Marczylo TH, Bell SC, et al. The endocan- nabinoid 2-arachidonoylglycerol (2-AG) and me- tabolizing enzymes during rat fetoplacental de- velopment: a role in uterine remodelling. Int J Biochem Cell Biol. 2010; 42(11):1884-92.
Talwar R, Potluri VK. Cannabinoid 1 (CB1) recep- tor--pharmacology, role in pain and recent devel- opments in emerging CB1 agonists. CNS Neurol Disord Drug Targets. 2011; 10(5):536-44.
Marco EM, Romero-Zerbo SY, Viveros MP, Bermu- dez-Silva FJ. The role of the endocannabinoid sys- tem in eating disorders: pharmacological implica- tions. Behav Pharmacol. 2012; 23(5-6):526-36.
Bilkei-Gorzo A. The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3326-41.
Montecucco F, Di Marzo V. At the heart of the mat- ter: the endocannabinoid system in cardiovascu- lar function and dysfunction. Trends Pharmacol Sci. 2012; 33(6):331-40.
Zogopoulos P, Vasileiou I, Patsouris E, Theocharis SE. The role of endocannabinoids in pain modula- tion. Fundam Clin Pharmacol. 2013; 27(1):64-80.
Lederer CM. The use of marijuana to treat glau- coma. Missouri Medicine. 2012; 109(2):95.
Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011; 124(4):250-61.
Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. Br J Phar- macol. 2011; 163(7):1411-22.
Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. Drug Testing and Analy- sis. 2013, (Doi: 10.1002/dta.1506).
Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009; 374(9698):1383-91.
Buys YM, Rafuse PE. Canadian Ophthalmological Society policy statement on the medical use of marijuana for glaucoma. Can J Ophthalmol. 2010; 45(4):324-6.
Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural can- nabinoids. Life Sci. 2005; 78(5):539-48.
Russo EB, Burnett A, Hall B, Parker KK. Agonis- tic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005; 30(8):1037-43.
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and car- diovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005; 365(9468):1389-97.
Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabi- noid receptor blockade improves cardiometabol- ic risk in mouse models of obesity. J Clin Invest. 2010; 120(8):2953-66.
Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knock- out in mice leads to leanness, resistance to diet- induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004; 28(4):640-8.
Sam AH, Salem V, Ghatei MA. Rimonabant: From RIO to Ban. J Obes. 2011;2011:432607.
Moreira FA, Crippa JA. The psychiatric side- effects of rimonabant. Rev Bras Psiquiatr. 2009; 31(2):145-53.
Alonso M, Serrano A, Vida M, Crespillo A, Her- nandez-Folgado L, Jagerovic N, et al. Anti-obesity efficacy of LH-21, a cannabinoid CB(1) recep- tor antagonist with poor brain penetration, in diet-induced obese rats. Br J Pharmacol. 2012; 165(7):2274-91.
Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, et al. Activation of the periph- eral endocannabinoid system in human obesity. Diabetes. 2005; 54(10):2838-43.
Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, et al. Discovery of a potent, selec- tive, and efficacious class of reversible alpha- ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem. 2005; 48(6):1849-56.
De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V. Overlap between the ligand recog- nition properties of the anandamide transport- er and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS letters. [Research Support, Non- U.S. Gov’t]. 2000; 483(1):52-6.
Tambaro S, Bortolato M. Cannabinoid-related agents in the treatment of anxiety disorders: cur- rent knowledge and future perspectives. Recent Pat CNS Drug Discov. 2012; 7(1):25-40.
[cited 2013 22/02/2013]; Available from: http:// clinicaltrials.gov/ct2/show/NCT01618656.
